×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Almirall signs yes-nonsense deal with Eloxx for $3M upfront
Fierce Biotech
Almirall is handing over $3 million for Eloxx Pharmaceuticals' molecule for a pair of rare skin diseases just before the drug enters the...
2 months ago
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
Yahoo Finance
ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome...
1 month ago
Almirall to license Eloxx's ZKN-013 for rare skin conditions
Pharmaceutical Technology
Almirall has signed a licence agreement to gain the rights for Eloxx Pharmaceuticals' ZKN-013 for rare dermatological disease indications.
2 months ago
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological ...
Business Wire
Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive...
2 months ago
Almirall And Eloxx Pharmaceuticals Enter Exclusive License Agreement For ZKN-013
Contract Pharma
Almirall S.A. and Eloxx Pharmaceuticals Inc. have entered into an exclusive license agreement for the asset ZKN-013. Under the agreement,...
2 months ago
Almirall gains rights to Eloxx’s rare dermatological disease asset in deal worth over $470m
PMLiVE
ZKN-013 is designed to overcome nonsense mutations in rare skin diseases such as junctional epidermolysis bullosa.
2 months ago
Scilex (NASDAQ:SCLX) & Eloxx Pharmaceuticals (NASDAQ:ELOX) Head to Head Survey
Defense World
Read Scilex (NASDAQ:SCLX) & Eloxx Pharmaceuticals (NASDAQ:ELOX) Head to Head Survey at Defense World.
2 weeks ago
Is Eloxx Pharmaceuticals (NASDAQ:ELOX) Weighed On By Its Debt Load?
Yahoo Lifestyle Canada
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
2 weeks ago
Eloxx reports all patients in Phase II Alport syndrome trial have improved
Clinical Trials Arena
Eloxx Pharmaceuticals has reported that all patients in the Phase II trial showed improvement in podocyte foot process effacement.
9 months ago
Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport ...
FOX 2
Eloxx Pharmaceuticals, Inc. is engaged in the science of ribosome modulation, leveraging its innovative TURBO-ZM™ chemistry technology platform...
9 months ago